Fig. 5

A Overview of the Topiramate study, in which the patients were treated with three different dosages of the weight-loss drug topiramate, and instructed to eat on average 600 kcal less per day and also took different dosages of the weight loss drug Topiramate. The results of the model training and validation on topiramate data are shown as purple lines for the best simulation, purple error bars for the data, and shaded purple areas for model uncertainty, for the B fit to placebo data, C fit to weight data for Topiramate dosages 64 mg/day and 192 mg/day, and D model validation on Topiramate dosage 96 mg/day, where the validation data is shown as gray error bars. The first data point was used to set initial conditions for the corresponding simulations. E The trained model was used to make predictions made for two different scenarios not done during the Topiramate study: increasing the energy intake with 1200 kcal/day for 1 year, without topiramate treatment (solid purple line) and with 192 mg/day topiramate treatment (dashed purple line). F Predictions of meal responses before the predicted diet and topiramate intervention (blue solid line), after 1 year of energy intake increase without treatment (red solid line) and with treatment (purple dashed line) for \(\mathrm{plasma insulin}\) and \(\mathrm{plasma glucose}\) on the organ/tissue level, and G \(\mathrm{IRS}1-\mathrm{p}\) and \(\mathrm{PKB}308-\mathrm{p}\) on the cell level